Antiplatelet Therapy in Cardiovascular Diseases

Antiplatelet therapy is essential in preventing arterial blockages that can lead to serious conditions such as heart attacks, strokes, and peripheral artery disease. Traditionally, aspirin and clopidogrel have been the mainstays of treatment, but advancements have introduced more potent options like prasugrel, ticagrelor, and glycoprotein IIb/IIIa inhibitors. Researchers are also exploring newer agents-such as intravenous Conqueror and protease-activated receptor-1 antagonists-to further enhance treatment strategies. Each antiplatelet drug works differently. Aspirin prevents clot formation by blocking a key enzyme, while clopidogrel requires metabolic activation to become effective. Newer drugs like prasugrel and ticagrelor act faster and are often more effective, particularly in emergency situations. However, selecting the right therapy is complex and depends on several factors, including a patient’s genetics, which can influence both drug response and the risk of side effects. As the field evolves, newer medications are expanding the options for preventing blood clots while carefully balancing the risk of bleeding. Ongoing research remains crucial-not only to refine treatment strategies but also to explore aspirin’s emerging role in cancer prevention. Personalized therapy is the future, ensuring that patients receive the most effective and safest treatment based on their individual needs.